List of Atea Pharmaceuticals, Inc. patents

Patents where

Current Assignee

Name

Atea Pharmaceuticals, Inc.

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11707480 Highly active compounds against COVID-19	Patent 11707480 was granted and assigned to Atea Pharmaceuticals, Inc. on July, 2023 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	11707480	July 25, 2023
‌ US Patent 11690860 Treatment of HCV infected patients with cirrhosis	Patent 11690860 was granted and assigned to Atea Pharmaceuticals, Inc. on July, 2023 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	11690860	July 4, 2023
‌ US Patent 12006340 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus	Patent 12006340 was granted and assigned to Atea Pharmaceuticals, Inc. on June, 2024 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	12006340	June 11, 2024
‌ US Patent 10946033 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment	Patent 10946033 was granted and assigned to Atea Pharmaceuticals, Inc. on March, 2021 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	10946033	March 16, 2021
‌ US Patent 10519186 Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus	Patent 10519186 was granted and assigned to Atea Pharmaceuticals, Inc. on December, 2019 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	10519186	December 31, 2019
‌ US Patent 10239911 Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment	Patent 10239911 was granted and assigned to Atea Pharmaceuticals, Inc. on March, 2019 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	10239911	March 26, 2019
‌ US Patent 10874687 Highly active compounds against COVID-19	Patent 10874687 was granted and assigned to Atea Pharmaceuticals, Inc. on December, 2020 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	10874687	December 29, 2020
‌ US Patent 10005811 β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N	Patent 10005811 was granted and assigned to Atea Pharmaceuticals, Inc. on June, 2018 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	10005811	June 26, 2018
‌ US Patent 10000523 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N	Patent 10000523 was granted and assigned to Atea Pharmaceuticals, Inc. on June, 2018 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	10000523	June 19, 2018
‌ US Patent 10906928 Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus	Patent 10906928 was granted and assigned to Atea Pharmaceuticals, Inc. on February, 2021 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	10906928	February 2, 2021
‌ US Patent 9828410 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N	Patent 9828410 was granted and assigned to Atea Pharmaceuticals, Inc. on November, 2017 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	9828410	November 28, 2017
‌ US Patent 10815266 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N	Patent 10815266 was granted and assigned to Atea Pharmaceuticals, Inc. on October, 2020 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	10815266	October 27, 2020
‌ US Patent 10870673 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N	Patent 10870673 was granted and assigned to Atea Pharmaceuticals, Inc. on December, 2020 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	10870673	December 22, 2020
‌ US Patent 10894804 Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus	Patent 10894804 was granted and assigned to Atea Pharmaceuticals, Inc. on January, 2021 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	10894804	January 19, 2021
‌ US Patent 10875885 β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n	Patent 10875885 was granted and assigned to Atea Pharmaceuticals, Inc. on December, 2020 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	10875885	December 29, 2020
‌ US Patent 10870672 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment	Patent 10870672 was granted and assigned to Atea Pharmaceuticals, Inc. on December, 2020 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	10870672	December 22, 2020
‌ US Patent 10711029 Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection		Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	10711029	July 14, 2020
‌ US Patent 10202412 β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N	Patent 10202412 was granted and assigned to Atea Pharmaceuticals, Inc. on February, 2019 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	10202412	February 12, 2019
‌ US Patent 11975016 2′-substituted-N	Patent 11975016 was granted and assigned to Atea Pharmaceuticals, Inc. on May, 2024 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	11975016	May 7, 2024
‌ US Patent 12084473 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment	Patent 12084473 was granted and assigned to Atea Pharmaceuticals, Inc. on September, 2024 by the United States Patent and Trademark Office.	Atea Pharmaceuticals, Inc.	Atea Pharmaceuticals, Inc.	United States Patent and Trademark Office	12084473	September 10, 2024

20 results

0 selected

20 results

0 selected